NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

That’s a fair analogy in tone, but the logic behind it deserves refinement.

If you call a police precinct and get referred to the county jail, that doesn’t mean the person is guilty. It means you were redirected to the department that manages custody records. Jurisdiction, not judgment.

Same principle applies here.

Being referred to the MHRA’s Variations Unit doesn’t imply rejection. It implies the product is already in the system. The Variations Unit doesn’t handle new applications. It handles updates to existing ones, things like manufacturing changes, site additions, labeling adjustments, and most critically:

Activation of named-patient access under special legal frameworks.

And that’s where SI 2025 No. 87 changes the game.

Under this statute, the MHRA can authorize patient-specific advanced therapies (like DCVax) without requiring full market authorization, so long as:

• Each dose is tied to a named patient
• The manufacturing site holds a Control Site license
• The product complies with GMP and traceability standards

No CHMP review. No traditional MAA.
Just a new legal pathway, quietly enacted for exactly this scenario.

So if you contact the MHRA and get referred to “variations,” the rational interpretation isn’t “something went wrong.” It’s:

Something is already in motion.
And it’s being managed under a framework that allows for modular deployment, not a binary yes/no approval.

This doesn’t mean the company isn’t navigating final regulatory steps.
It means they’re likely doing so within a legal structure that was built to let this happen quietly (and lawfully)before anyone rings a bell.

The referral doesn’t weaken the case.
If you understand SI 87, it strengthens it.


Also, if you’re willing, would you be open to sharing the full text of your MHRA exchange or referral? It might help others understand the wording and context more clearly.